Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Accrued royalties payable Accrued Royalties, Current Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Equity Award [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Going Concern Liquidity [Policy Text Block] Liquidity Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Defined contribution plan, employer matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Effect of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Contract to perform for others, costs incurred, gross Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Option exercisable, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term At The Market Equity Offering At The Market Equity Offering [Member] At The Market Equity Offering Restatement Determination Date: Restatement Determination Date [Axis] Stock compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Accrued clinical expense Accrued Clinical Expense, Current Accrued Clinical Expense, Current Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Commitments and contingencies (Note 12) Commitments and Contingencies Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Insider Trading Policies and Procedures [Line Items] Options exercisable, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Shares issued, price per share Shares Issued, Price Per Share Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Milestone payments, contingent amount Milestone Payments, Contingent Amount Milestone payments, contingent amount. Weighted- Average Remaining Contractual Life (Years) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Roll Forward Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term roll forward. Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Options vested and expected to vest, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Options exercisable, ending (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Grant Date Fair Value Other non-current assets Increase (Decrease) in Other Noncurrent Assets Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Issuance of common stock from the exercise of warrants (in shares) Issuance Of Common Stock From Exercise Of Warrants, Shares Issuance Of Common Stock From Exercise Of Warrants, Shares Income Taxes Income Tax Disclosure [Text Block] Pear Tree Pharmaceuticals, Inc. Pear Tree Pharmaceuticals, Inc. [Member] Pear Tree Pharmaceuticals, Inc. Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Restricted cash included in other non-current assets Restricted Cash and Cash Equivalents, Noncurrent Concentration Risk [Line Items] Concentration Risk [Line Items] Project [Domain] Project [Domain] Leases Lessee, Leases [Policy Text Block] Sale of stock, brokerage commissions expense Sale Of Stock, Brokerage Commissions Expense Sale Of Stock, Brokerage Commissions Expense Customer [Axis] Customer [Axis] Current Liabilities Liabilities, Current [Abstract] Prepaid development expense Prepaid Development Expense, Current Prepaid Development Expense, Current March 2023 At The Market Sales Agreement March 2023 At The Market Sales Agreement [Member] March 2023 At The Market Sales Agreement Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock issued Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] PEO Total Compensation Amount PEO Total Compensation Amount Options vested and expected to vest, ending (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Grant, DARE-FRT1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Interest rate on insurance financing Insurance Financing, Interest Rate Insurance Financing, Interest Rate Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leased Properties Lessee, Operating Leases [Text Block] Liabilities and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Stockholders' equity (deficit) Equity, Attributable to Parent [Abstract] State tax rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Schedule of Reconciliation of the Beginning and Ending Amount of Uncertain Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Exercised Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Executive Category: Executive Category [Axis] Deposits Deposits Assets, Noncurrent Amount awarded for grant Proceeds From Award Of Grants Proceeds From Award Of Grants Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Name Forgone Recovery, Individual Name Issuance of common stock warrants, net of issuance costs Adjustments to Additional Paid in Capital, Warrant Issued Equity Components Equity Components [Axis] Exercise Price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Research Credit Carryforwards Research Tax Credit Carryforward [Member] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses Increase (Decrease) in Accrued Liabilities Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Measurement Basis [Axis] Measurement Basis [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Payment to be received upon termination without cause Employment Agreement, Salary Payment Received Upon Termination Without Cause Employment Agreement, Salary Payment Received Upon Termination Without Cause Measurement Frequency [Axis] Measurement Frequency [Axis] Warrant Warrant [Member] Lease liabilities long-term Operating Lease, Liability, Noncurrent Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Class of Warrant or Right [Table] Class of Warrant or Right [Table] Depreciation expense Depreciation Payment to be received upon termination for cause or for good reason Employment Agreement, Salary Payment Received Upon Termination for Cause or Good Reason Employment Agreement, Salary Payment Received Upon Termination for Cause or Good Reason Research and development agreement, commitment, amount Research and Development Agreement, Commitment, Amount Research and Development Agreement, Commitment, Amount Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net Proceeds From Issuance Of Common Stock And Warrants Income Statement Location [Axis] Income Statement Location [Axis] Research and development credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Additional investment amount Class Of Warrant Or Right, Supplement Investment Class Of Warrant Or Right, Supplement Investment Outstanding and exercisable, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms Registration payment arrangement, maximum potential consideration Registration Payment Arrangement, Maximum Potential Consideration Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Future Minimum Lease Payment Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Class of warrant or right, extent holder own percentage Class of Warrant or Right, Extent Holder Own Percentage Class of Warrant or Right, Extent Holder Own Percentage Number of significant performance obligations Revenue, Number Of Significant Performance Obligations Revenue, Number Of Significant Performance Obligations Sale of stock, number of shares issued in transaction Sale of stock, number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Aggregate commission rate Percentage Of Aggregate Commission Percentage of aggregate commission. Proceeds from the sale of future royalties, net Proceeds From Sale Of Future Royalties, Net Proceeds From Sale Of Future Royalties, Net Payables and Accruals [Abstract] Payables and Accruals [Abstract] Total revenue Revenues Measurement Input, Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Class of warrant or right, exercises Class Of Warrant Or Right, Exercises Class Of Warrant Or Right, Exercises Accrued development expense Accrued Development Expense, Current Accrued Development Expense, Current Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] CRADA CRADA [Member] CRADA Award Type [Axis] Award Type [Axis] Plan Name [Domain] Plan Name [Domain] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative General and Administrative Expense [Member] Options to purchase number of outstanding shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Outstanding, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Upon Achieving Certain Clinical And Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Royalty payments Payments for Royalties Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Summary of Components of Loss from Continuing Operations Before Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Entity File Number Entity File Number Number of additional payment Royalty Agreement, Number Of Additional Payments Royalty Agreement, Number Of Additional Payments October 2021 At The Market Sales Agreement October 2021 At The Market Sales Agreement [Member] October 2021 At The Market Sales Agreement Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Class of warrant or right, extent holder own percentage Class of Warrant or Right, Holder Election Percentage Class of Warrant or Right, Holder Election Percentage Current portion of lease liabilities Operating Lease, Liability, Current Prepaid expenses Total prepaid expenses Prepaid Expense, Current License fee revenue License [Member] Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Advanced written notice period Upfront License Fee, Advanced Written Notice, Period Upfront License Fee, Advanced Written Notice, Period Prior year - reductions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Bayer Healthcare LLC Bayer Healthcare LLC [Member] Bayer Healthcare LLC Prepaid expenses Increase (Decrease) in Prepaid Expense Current year - increases Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash, beginning of year Cash, cash equivalents and restricted cash, end of year Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Outstanding and exercisable (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding And Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding And Exercisable Measurement Input, Expected Term Measurement Input, Expected Term [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Operating lease cost Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Health insurance premium Health Insurance Premiums, Monthly Amount Health Insurance Premiums, Monthly Amount Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees, and Non-Employee Directors Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Research and development expense credit Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Net proceeds from sale of stock offering Sale of Stock, Consideration Received on Transaction Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Forfeited or expired Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Stock Options Employee Stock Option [Member] Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Tabular List, Table Tabular List [Table Text Block] Federal Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One Operating loss carryforward, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Entity Address, Address Line Two Entity Address, Address Line Two Accrued indemnification provisions Accrued Indemnification Provisions Accrued indemnification provisions. Initial payment Grants Receivable Non-cash interest expense on liability related to sale of future royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Subsequent Event [Table] Subsequent Event [Table] Consulting agreement term Consulting Agreement, Term Consulting Agreement, Term Stock-based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Subsequent Event Subsequent Event [Member] Accrued interest or penalties recorded related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Net operating loss carryforwards Operating Loss Carryforwards Merger Agreement Merger Agreement [Member] Merger Agreement Premiums, taxes and fees Insurance Financing, Premiums, Taxes And Fees, Amount Insurance Financing, Premiums, Taxes And Fees, Amount Income Statement [Abstract] Income Statement [Abstract] Issuance of common stock and warrants, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Number of experts License Agreement, Number Of Experts License Agreement, Number Of Experts Warrants and Rights Note Disclosure [Abstract] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Related Party [Domain] Related Party, Type [Domain] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Class of warrant or right, number of securities called by each warrant or right Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Working capital deficit Working Capital Increase (Deficit) Working Capital Increase (Deficit) Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Expiration period License Agreement, Expiration Period License Agreement, Expiration Period Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Major Vendor Major Vendor [Member] Major Vendor Reimburse amount, PDUFA fees and other manufacturing expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Statistical Measurement [Axis] Statistical Measurement [Axis] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Entity Interactive Data Current Entity Interactive Data Current Supplemental investment (in shares) Class Of Warrant Or Right, Supplement Investment Share Amount Class Of Warrant Or Right, Supplement Investment Share Amount 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Liability related to the sale of future royalties, net Liability related to the sale of future royalties Royalty Guarantees, Commitments, Amount Total Shareholder Return Amount Total Shareholder Return Amount Lease term Lessor, Operating Lease, Term of Contract Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Cash balance of financial institutions insured by federal deposits insurance corporation Cash, FDIC Insured Amount Amortized weighted average period Weighted Average Amortization Period Weighted Average Amortization Period Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accrued license fee expense Accrued License Expense, Current Accrued License Expense, Current Current Assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Summary of Major Components of Company's Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Health coverage to be received upon termination without cause Employment Agreement, Health Benefits Coverage Received Upon Termination Without Cause Employment Agreement, Health Benefits Coverage Received Upon Termination Without Cause Change in control of company, termination without cause or resignation for good reason, period Employment Agreement, Change In Control Of Company, Termination Without Cause Or Resignation For Good Reason Employment Agreement, Change In Control Of Company, Termination Without Cause Or Resignation For Good Reason, Period Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Operating lease, payments Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Other expense attributed to cost of revenue Other Cost and Expense, Operating Issuance cost recorded under additional-paid-in-capital Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Milestone payments Research And Development, Milestone Payment Research and development milestone payment. Capitalized research and development costs Deferred Tax Assets Capitalized Research And Development Cost Deferred Tax Assets Capitalized Research And Development Cost Deferred grant funding Deferred Grant Funding, Current Deferred Grant Funding, Current Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Customer [Domain] Customer [Domain] Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Net loss to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Number of Shares Underlying Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Collaborative Arrangement Collaborative Arrangement [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Total operating lease liabilities Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Total liabilities Liabilities Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid legal and professional expenses Prepaid Professional Expense, Current Prepaid Professional Expense, Current Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Common stock reserved for issuance (in shares) Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance All Executive Categories All Executive Categories [Member] Deferred revenue, non-current Contract with Customer, Liability, Noncurrent Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] License fee expense License Fee Expense License Fee Expense Related Party Transaction Related Party Transaction [Domain] Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Subsequent Event [Line Items] Subsequent Event [Line Items] Number of Shares Underlying Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Common stock, $0.0001 par value, 240,000,000 shares authorized, 99,973,932 and 84,825,481 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Accrued legal and professional Accrued Professional Fees, Current Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current All Individuals All Individuals [Member] Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Quarterly payment period Royalty Agreement, Quarterly Payments, Period Royalty Agreement, Quarterly Payments, Period Health coverage to be received upon termination for cause or for good reason Employment Agreement, Health Benefits Coverage Received Upon Termination for Cause or Good Reason Employment Agreement, Health Benefits Coverage Received Upon Termination for Cause or Good Reason Other income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical And Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Exercise of Options Outstanding Exercise Of Options Outstanding [Member] Exercise of options outstanding. Difference Between Provision for Income Taxes (Benefit) and the Amount Computed by Applying U.S. Federal Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Unrecognized tax benefits Beginning uncertain tax benefits Ending uncertain tax benefits Unrecognized Tax Benefits Income Tax Authority Income Tax Authority [Axis] PEO Name PEO Name Concentration risk percentage Concentration Risk, Percentage Biotherapeutic Foundation Biotherapeutic Foundation [Member] Biotherapeutic Foundation Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Operating lease, incremental borrowing rate, prime rate Operating Lease, Incremental Borrowing Rate, Prime Rate Operating Lease, Incremental Borrowing Rate, Prime Rate State income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Internal rate of return Royalty Agreement, Internal Rate Of Return Royalty Agreement, Internal Rate Of Return Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Prepaid insurance expense Prepaid Insurance Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Increase (decrease) In operating lease right-of-use asset Increase (Decrease) In Operating Lease Right-of-Use Asset Increase (Decrease) In Operating Lease Right-of-Use Asset Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] United United in Endeavor, LLC [Member] United in Endeavor, LLC Other accruals Other Accrued Liabilities, Current Measurement Input, Expected Dividend Payment Measurement Input, Expected Dividend Payment [Member] Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Total accrued expenses Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] License fee, agreement retention, minimum required amount to be received License Fee, Agreement Retention, Minimum Required Amount To Be Received License Fee, Agreement Retention, Minimum Required Amount To Be Received Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Outstanding and exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable Registered Direct Offering Registered Direct Offering [Member] Registered Direct Offering Consulting Agreement Consulting Agreement [Member] Consulting Agreement Total stockholders' equity (deficit) Beginning balance Ending balance Equity, Attributable to Parent Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Valuation allowance Deferred tax valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Percentage of royalty rate Royalty Rate, Percentage Percentage of royalty rate. Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Phase II Segment Phase II Segment [Member] Phase II Segment Loss before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Subsequent Events [Abstract] Subsequent Events [Abstract] MBI MBI [Member] MBI Warrants and rights outstanding, measurement input Warrants and Rights Outstanding, Measurement Input Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Debt issuance cost Debt Issuance Costs, Net Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities [Member] Insurance financing payable Insurance Financing Payable Insurance Financing Payable Total deferred tax assets Deferred Tax Assets, Gross Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Milestone payment revenues Milestone Payment Revenues Milestone Payment Revenues 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Title Trading Arrangement, Individual Title Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common stock Common Stock [Member] Warrant, exercise price, decrease Warrant, Exercise Price, Decrease Individual: Individual [Axis] Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Royalty revenue Royalty [Member] Issuance of note payable Proceeds from Notes Payable Sale of stock, prospectus offering amount Sale Of Stock, Prospectus Offering Amount Sale Of Stock, Prospectus Offering Amount Document Fiscal Year Focus Document Fiscal Year Focus Weighted Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Minimum Minimum [Member] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property, Plant and Equipment, Net Receivables [Abstract] Receivables [Abstract] License And Collaboration Revenues License And Collaboration Revenues [Member] License And Collaboration Revenues Summary of Stock Option Activity for 2015 Plan and Current Plan and Related Information Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Schedule of Warrant Activity Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Two Thousand Twenty Two Stock Incentive Plan Two Thousand Twenty Two Stock Incentive Plan [Member] Two Thousand Twenty Two Stock Incentive Plan Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Juniper Pharmaceuticals, Inc. Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Increase (decrease) in operating lease liability Increase (Decrease) in Operating Lease Liability Other Deferred Tax Assets, Other Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Monthly payments under consulting agreement Consulting Agreement, Monthly Payments Consulting Agreement, Monthly Payments Accumulated Deficit Retained Earnings [Member] Payments to stockholders' representative in business combination Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Indemnification Obligations Guarantees, Indemnifications and Warranties Policies [Policy Text Block] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders' equity (deficit) Liabilities and Equity Australian Taxation Office Australian Taxation Office [Member] Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Loss per common share - basic (in usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Risks and Uncertainties Risks And Uncertainties [Policy Text Block] Risks and uncertainties Accounting Policies [Abstract] Accounting Policies [Abstract] Net operating loss carryforwards expiration year Operating Loss Carryforwards Expiration Period Operating loss carryforwards expiration period. Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Grant, ADARE-204 and ADARE-214 Grant, ADARE-204 and ADARE-214 [Member] Grant, ADARE-204 and ADARE-214 Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Warrant term Warrants and Rights Outstanding, Term Asset acquisition, contingent consideration, current Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Royalty Investment Financing Agreement Royalty Investment Financing Agreement [Member] Royalty Investment Financing Agreement Arrangement Duration Trading Arrangement Duration Change in control of company, termination for cause or for good reason Employment Agreement, Change in Control of Company, Termination for Cause or Good Reason Employment Agreement, Change in Control of Company, Termination for Cause or Good Reason Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Sale Of Future Royalties Sale Of Future Royalties [Text Block] Sale Of Future Royalties Options vested and expected to vest, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Principles of Consolidation Consolidation, Policy [Policy Text Block] Operating loss carryforwards not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Royalty revenue Royalty Revenue [Member] Royalty Revenue Entity Public Float Entity Public Float Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Hard cap rate Royalty Agreement, Hard Cap, Percentage Royalty Agreement, Hard Cap, Percentage Deferred tax assets, increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Issuable upon additional investment made number of securities called by warrants Class Of Warrant Or Right, Initial Royalty Warrant Issued Class Of Warrant Or Right, Initial Royalty Warrant Issued Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Supplier Concentration Risk Supplier Concentration Risk [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Milestone payments rate Royalty Agreement, Milestone Payments, Percentage Royalty Agreement, Milestone Payments, Percentage Award Timing Disclosures [Line Items] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Annual percentage increase in outstanding number of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Other Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent Compensation Amount Outstanding Recovery Compensation Amount Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Milestone revenue Milestone Revenue [Member] Milestone Revenue Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value Roll Forward Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value. Gain on early termination of lease Gain on termination of lease Gain (Loss) on Termination of Lease Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] DARE-LBT DARE-LBT [Member] DARE-LBT Research credit carryforwards expiration year Tax Credit Carryforward Expiration Period Tax credit carry forward expiration period. Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Other receivables Increase (Decrease) in Other Receivables Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income Taxes Income Tax, Policy [Policy Text Block] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Equity issued in consideration of acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Defined contribution plan, employer matching contribution, percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Insider Trading Arrangements [Line Items] Prepaid Expenses Other Current Assets [Text Block] Audit Information [Abstract] Audit Information Related Party [Axis] Related Party, Type [Axis] Outstanding, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Forfeited or expired Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid Warrants and rights outstanding (in shares) Relative fair value of Initial Royalty Warrant Warrants and Rights Outstanding Adjustment to Compensation, Amount Adjustment to Compensation Amount Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Auditor Name Auditor Name Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Unamortized stock-based compensation expense Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Options exercisable, ending (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Net royalty payments rate Royalty Agreement, Net Royalty Payments, Percentage Royalty Agreement, Net Royalty Payments, Percentage Entity Central Index Key Entity Central Index Key Vendor Concentration Concentration Risk Disclosure [Text Block] Research credit carryforward, subject To expiration Tax Credit Carry Forward, Subject To Expiration Tax Credit Carry Forward, Subject To Expiration Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Supplemental investment payment Royalty Agreement, Supplement Investment Payment Royalty Agreement, Supplement Investment Payment Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax provision Income Tax Expense (Benefit) Outstanding, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Income Tax Authority Income Tax Authority [Domain] Grant, DARE-PTB2 Grant, DARE-PTB2 [Member] Grant, DARE-PTB2 Accrued compensation and benefits Employee-related Liabilities, Current Proceeds from royalties received Upfront payment from the sale of future royalties Proceeds from Royalties Received Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Hennepin License Agreement Hennepin License Agreement [Member] Hennepin License Agreement Grant Awards Grant Award [Text Block] Grant Award [Text Block] NICHD NICHD [Member] NICHD Issuance of common stock and warrants, net of issuance costs Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Risks and Uncertainties [Abstract] Milestone payments, contingent amount, first commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other Receivables, Net, Current Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Schedule of Changes in the Liability Related to the Sale of Future Royalties Schedule Of Changes In The Liability Related To The Sale Of Future Royalties [Table Text Block] Schedule Of Changes In The Liability Related To The Sale Of Future Royalties Square feet of office space Net Rentable Area Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Phase I Segment Phase I Segment [Member] Phase I Segment Research credit carryforwards Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payments on note payable Repayments of Notes Payable Weighted average interest rate Operating Lease, Weighted Average Discount Rate, Percent Licensing Agreements Licensing Agreements [Member] Permanent differences Effective Income Tax Rate Reconciliation, Permanent Differences Effective income tax rate reconciliation, permanent differences. Prepaid clinical expense Prepaid Clinical Expense, Current Prepaid Clinical Expense, Current Upon Achievement Of Specified Development And Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Warrants Warrants [Member] Warrants Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Operating expenses Operating Expenses [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Estimated fair value of warrants Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Unremitted earnings Unremitted Earnings Unremitted earnings. Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Commitments and Contingencies Commitments Disclosure [Text Block] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Grant funding recognized during period Grant Funding Recognized During Period Grant Funding Recognized During Period Cover [Abstract] Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Subsequent Events Subsequent Events [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Tax Credit Carryforward, Name Tax Credit Carryforward, Name [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Non-NEOs Non-NEOs [Member] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Issuance of common stock from the exercise of warrants Issuance Of Common Stock From Exercise Of Warrants, Amount Issuance Of Common Stock From Exercise Of Warrants, Amount Total operating expenses Operating Expenses Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Non-PEO NEO Non-PEO NEO [Member] Renewal term of operating lease Lessee, Operating Lease, Renewal Term Equity Component Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Project [Axis] Project [Axis] Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule of common stock reserved for future issuance State State and Local Jurisdiction [Member] Research and development credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations Operating Income (Loss) Reclassification of Prior Year Presentation Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Revenue Revenues [Abstract] Douglas License Agreement Douglas License Agreement [Member] Douglas License Agreement Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Effective annual interest rate Royalty Agreement, Effective Annual Interest Rate, Percentage Royalty Agreement, Effective Annual Interest Rate, Percentage Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Related Party Transaction Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Options vested and expected to vest, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Organon Organon [Member] Organon Deposits Increase (Decrease) in Deposit Assets Payment of additional consideration in business combination Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination Tax Credit Carryforward Tax Credit Carryforward [Axis]